Literature DB >> 25716958

Effects of depression on the cytokine profile in drug naïve first-episode psychosis.

Cristiano Noto1, Vanessa Kiyomi Ota2, Marcos Leite Santoro2, Bruno B Ortiz3, Lucas B Rizzo3, Cinthia Hiroko Higuchi3, Quirino Cordeiro1, Sintia Iole Belangero2, Rodrigo Affonseca Bressan3, Ary Gadelha3, Michael Maes4, Elisa Brietzke5.   

Abstract

Schizophrenia is accompanied by alterations in immuno-inflammatory pathways, including abnormalities in cytokine profile. The immune assessment of patients in a first episode of psychosis (FEP) and particularly in drug naïve patients is very important to further elucidate this association. The objectives of this study are to delineate the cytokine profile (IL-2, IL-10, IL-4, IL-6, IFNγ, TNFα and IL-17) in FEP patients (n=55) versus healthy controls (n=57) and to examine whether the presence of depressive symptoms in FEP is accompanied by a specific cytokine profile. We found increased levels of IL-6, IL-10 and TNFα in FEP patients when compared to healthy controls. FEP patients with depression showed higher IL-4 and TNFα levels versus those without depression. Cytokine levels were not correlated to the total PANSS and the positive or negative subscale scores. Our results suggest that FEP is accompanied by a cytokine profile indicative of monocytic and T regulatory cell (Treg) activation. Depression in FEP is accompanied by monocytic and Th-2 activation, whereas FEP without depression is characterized by Treg activation only. In conclusion, depression emerged as a key component explaining the cytokines imbalance in FEP that is responsible for a large part of the immune-inflammatory abnormalities described.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokines; Depression; Drug naïve; First-episode psychosis (FEP); Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25716958     DOI: 10.1016/j.schres.2015.01.026

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

1.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

2.  Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis.

Authors:  Xinyu Fang; Yi Zhang; Weixing Fan; Wei Tang; Chen Zhang
Journal:  Mol Neuropsychiatry       Date:  2017-10-28

3.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

4.  Changes in inflammation are related to depression and amount of aerobic exercise in first episode schizophrenia.

Authors:  Joseph Ventura; Sarah McEwen; Kenneth L Subotnik; Gerhard S Hellemann; Manali Ghadiali; Amir Rahimdel; Min Jee Seo; Michael R Irwin; Keith H Nuechterlein
Journal:  Early Interv Psychiatry       Date:  2020-02-13       Impact factor: 2.732

5.  A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?

Authors:  Elfi Vergaelen; Carmen Schiweck; Kristof Van Steeland; Jacqueline Counotte; Wim Veling; Ann Swillen; Hemmo Drexhage; Stephan Claes
Journal:  Brain Behav Immun       Date:  2018-03-19       Impact factor: 7.217

6.  Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia.

Authors:  Cigdem Sahbaz; Noushin Zibandey; Ayse Kurtulmus; Yazgul Duran; Muazzez Gokalp; Ismet Kırpınar; Fikrettin Sahin; Sinan Guloksuz; Tunc Akkoc
Journal:  Psychopharmacology (Berl)       Date:  2020-03-27       Impact factor: 4.530

7.  Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis.

Authors:  Cristiano Noto; Vanessa Kiyomi Ota; Marcos Leite Santoro; Eduardo Sauerbronn Gouvea; Patricia Natalia Silva; Leticia Maria Spindola; Quirino Cordeiro; Rodrigo Affonseca Bressan; Ary Gadelha; Elisa Brietzke; Sintia Iole Belangero; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-10-22       Impact factor: 5.590

Review 8.  Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Authors:  Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg
Journal:  Behav Brain Res       Date:  2021-01-14       Impact factor: 3.332

Review 9.  Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue?

Authors:  Rachel Upthegrove; Steven Marwaha; Max Birchwood
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

10.  Increased Oxidative Stress Toxicity and Lowered Antioxidant Defenses in Temporal Lobe Epilepsy and Mesial Temporal Sclerosis: Associations with Psychiatric Comorbidities.

Authors:  Michael Maes; Thitiporn Supasitthumrong; Chusak Limotai; Ana Paula Michelin; Andressa Keiko Matsumoto; Laura de Oliveira Semão; João Victor de Lima Pedrão; Estefânia Gastaldello Moreira; Andre F Carvalho; Sunee Sirivichayakul; Décio Sabbatini Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-06-09       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.